TOI ONCOLOGY INSTITUTE INC (THE)

The Oncology Institute Launches Lung Cancer Center of Excellence in Florida Led by International Oncology Expert Dr. Edgardo Santos

The Oncology Institute Launches Lung Cancer Center of Excellence in Florida Led by International Oncology Expert Dr. Edgardo Santos

CERRITOS, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute of Hope and Innovation (NASDAQ: TOI), a leading value-based oncology practice, today announced the launch of its Lung Cancer Center of Excellence in Fort Lauderdale, Florida. The new center will be led by world-renowned thoracic oncologist Dr. Edgardo S. Santos Castillero, whose career has been defined by groundbreaking research, clinical excellence, and a deep commitment to patient care.

The Lung Cancer Center of Excellence provides patients across Florida with access to advanced treatments including clinical trials, delivered in a compassionate, community-based setting. By combining global expertise with local access, TOI delivers world-class cancer care and the personal connection of community oncology.

“Lung cancer remains one of the leading causes of cancer-related deaths, and patients deserve access to the latest therapies and expert care without the burden of traveling long distances,” said Dr. Santos. “At the Lung Cancer Center of Excellence, we bring advanced diagnostics, innovative treatments, and a whole-patient approach to South Florida so patients and their families can focus on healing.”

Dr. Santos, who has held leadership roles at Tulane University, the University of Miami/Sylvester Comprehensive Cancer Center, and the Lynn Cancer Institute, is internationally recognized as one of the foremost authorities in thoracic oncology. He has published extensively in peer-reviewed journals, serves on leadership committees for national and international oncology organizations, and is a sought-after speaker at oncology conferences worldwide.

“Our vision is to redefine lung cancer care by combining the most advanced value-based therapies with personalized, compassionate treatment,” said Daniel J. Virnich, Chief Executive Officer of The Oncology Institute. “The Lung Cancer Center of Excellence reflects TOI’s mission to expand access to high-quality cancer care across diverse communities, and improve clinical outcomes while lowering financial toxicity for patients and payor partners.”

About The Oncology Institute ():

Founded in 2007, The Oncology Institute (NASDAQ: TOI) is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. TOI offers cutting-edge, evidence-based cancer care to a population of approximately 1.9 million patients, including clinical trials, transfusions, and other care delivery models traditionally associated with the most advanced care delivery organizations. With over 180 employed and affiliate clinicians and over 100 clinics and affiliate locations of care across five states and growing, TOI is changing oncology for the better.

Media

The Oncology Institute, Inc.





Investors

ICR Healthcare



EN
02/09/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ONCOLOGY INSTITUTE INC (THE)

 PRESS RELEASE

The Oncology Institute Reports Fourth Quarter and Full Year 2025 Finan...

The Oncology Institute Reports Fourth Quarter and Full Year 2025 Financial Results and Guidance for 2026 CERRITOS, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), one of the largest value-based community oncology groups in the United States, today reported financial results for its fourth quarter and year ended December 31, 2025. Recent Operational Highlights Cash flow from operations in Q4 2025 was approximately $3.2 million, due to disciplined working capital management and overall increase in gross profit marginConti...

 PRESS RELEASE

The Oncology Institute Announces Fourth Quarter and Full Year 2025 Ear...

The Oncology Institute Announces Fourth Quarter and Full Year 2025 Earnings Release Date and Conference Call CERRITOS, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (“TOI”) (NASDAQ: TOI)  a pioneer in value-based community oncology care, today announced that the company will release its fourth quarter and full year 2025 financial results on Thursday, March 12, 2026, to be followed by a conference call the same day at 5:00 p.m. (Eastern Time). The conference call can be accessed live over the phone by dialing 1-877-407-0789 or for international callers, 1-201-689-...

 PRESS RELEASE

The Oncology Institute to Participate in Multiple Healthcare Investor ...

The Oncology Institute to Participate in Multiple Healthcare Investor Conferences in March CERRITOS, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI), a pioneer in value-based community oncology care, today announced that members of its executive leadership team will participate in several investor conferences in March. Details for the conferences are as follows: Jefferies Healthcare Services Innovation & Technology SummitPresentation: Monday, March 9, 2026, from 11:30 a.m. to 12:00 p.m. ETLocation: Miami, FLPresenter: Dr. Daniel Virnich, Chief Execut...

 PRESS RELEASE

The Oncology Institute Appoints Kim Tzoumakas to Board of Directors

The Oncology Institute Appoints Kim Tzoumakas to Board of Directors CERRITOS, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (“TOI”) (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, today announced the appointment of Kim Tzoumakas to its Board of Directors, effective February 23, 2026. Ms. Tzoumakas brings more than two decades of executive leadership experience across oncology, pharmacy services and healthcare operations. Notably, she is Chief Executive Officer for VytlOne National Pharmacy Services, and previously held the CEO r...

 PRESS RELEASE

The Oncology Institute Reaffirms 2025 Guidance and Provides Preliminar...

The Oncology Institute Reaffirms 2025 Guidance and Provides Preliminary 2026 Outlook CERRITOS, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), one of the largest value-based oncology groups in the United States, today reaffirmed 2025 guidance and provided its preliminary 2026 outlook. 2026 Outlook For 2026, TOI anticipates that total revenue will be in the range of $630 million to $650 million, reflecting 28% growth from the midpoint of 2025 and 2026 guidance ranges, and including approximately $150 million of Capitation rev...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch